Aspire-Lakewood vs Soligenix
ASBP and SNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ASBP and SNGX compare
Aspire-Lakewood is the larger company, worth 1.7 times as much as Soligenix ($11.8M against $7.0M).
Soligenix scores higher on the StockData Score (6 against 2 for Aspire-Lakewood), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ASBP | SNGX |
|---|---|---|
| Size and price | ||
| Market cap | $11.8M | $7.0M |
| Share price | $8.41 | $0.321 |
| Change, 1 year | 95.9% | −76.4% |
| Change, 5 years | – | −99.8% |
| Beta (5Y) | – | 0.61 |
| Employees | – | 14 |
| StockData Score | ||
| Total score | 2 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 121× | – |
| P/B | 1.0× (better) | 1.1× |
| Profitability | ||
| Gross margin | −25.0% | – |
| Operating margin | −7495% | – |
| Net margin | −11314% | – |
| Return on equity | −1032% | −127% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −0.8× | – |
| Current ratio | 7.99 (better) | 3.00 |
| Altman Z-score | −0.05 (better) | −38.47 |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | – | 4.3% |
| Held by insiders | 1.4% | 0.69% |
| Short interest, % of float | – | 0.31% |
Go deeper
- ASBP stock overview
- ASBP income statement
- ASBP valuation and score
- SNGX stock overview
- SNGX income statement
- SNGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.